For members enrolled in an IBC prescription drug program, prior authorization and quantity limit requirements will be applied to additional drugs. The purpose of prior authorization is to ensure that drugs are medically necessary and are being used appropriately. Quantity limits are designed to allow a sufficient supply of medication based upon the maximum daily dose and length of therapy approved by the U.S. Food and Drug Administration for a particular drug. The most recent updates are reflected below.

Drugs requiring prior authorization

The prior authorization requirement for the following non-formulary drugs was effective at the time the drugs became available in the marketplace: Brand drug Generic drug Drug category Effective date Caprelsa? Not available Cancer & Organ Transplant Drugs April 22, 2011 ZytigaTM Not available Cancer & Organ Transplant Drugs May 6, 2011

The following non-formulary drug will be added to the list of drugs requiring prior authorization for new prescriptions. Members taking this drug immediately prior to the effective date are not affected: Effective October 1, 2011. Brand drug Generic drug Drug category StaxynTM Not available Urinary & Prostate Meds

The following non-formulary drugs will be added to the list of drugs requiring prior authorization for new prescriptions: Effective October 1, 2011. Brand drug Generic drug Drug category Androderm? Not available Hormones Axiron? Not available Hormones FortestaTM Not available Hormones Striant? Not available Hormones Testim? Not available Hormones For members currently taking the above drugs, the prior authorization requirement will not be effective until January 1, 2012.

Drugs with quantity limits

Quantity limits will be added for the following drug: Effective October 1, 2011. Brand drug Generic drug Quantity limit (per 30 days) StaxynTM Not available 8 tablets